Rationale: Tongue metastasis from lung cancer is extremely rare, and the prognosis of these patients is rather poor.
Introduction
Lung cancer, of which 80% to 85% is non-small-cell lung cancer (NSCLC), is the leading cause of cancer-related mortality around the world. [1] Distant metastasis from primary lung cancer-e.g., to brain, liver, adrenals, or bone-is quite common; however, metastases to the tongue are relatively rare. [2] In a previous report, primary lung cancer metastasized to the tongue was found in 1.6% of 3047 cases. [3] About 5% of all malignant lesions were found in the oral cavity, [4] and 1% of them were from primary sites other than the oral cavity. [5] As tongue is a rare metastatic site, when a lesion is detected, a thorough evaluation to distinguish between metastasis or primary cancer should be made. [6] As lingual metastases tend to occur mostly in patients who have general dissemination of primary malignancies, [3] their prognoses tend to be poor. This study was approved by Committee on Ethics of Biomedicine, Second Military Medical University. This patient has given the informed consent of the study.
Case report
A 56-year-old male electric welder with an ongoing 30-pack-year smoking history was referred to the People's Hospital of Yancheng, Jiangsu province, with a complaint of cough with intermittent bloody sputum for 1 month and a half, without fever breathlessness or chest pain. No abnormalities were found in physical examination of his respiratory system. The thoracic computed tomography (CT) showed a 4-cm cavity lesion in the left upper lobe and multiple mediastinal lymphadenopathy. It was initially misdiagnosed as tuberculosis; subsequently, he accepted irregular antituberculosis treatment.
However, a week later, this patient became aware of a lump on the base of his tongue and experienced pain and hoarseness. He was therefore admitted to the Department of Respiratory Medicine, Changhai Hospital. Physical examination showed stiffness on the base of the tongue, but no ulcerated lump. Thoracic CT results were similar to b (Fig. 1A and B) . However, neck magnetic resonance imaging (MRI) showed a 3.6-cm infiltrating mass arising from the base of the tongue and multiple cervical lymphadenopathies (Fig. 1C and D) . The laryngoscope showed lymphoid tissue hyperplasia on the base of the tongue and the left vocal cords were fixed ( Fig. 2A and B) . CT-guided biopsy of lung lesion yields the diagnosis of squamous cell carcinoma (SCC; Fig. 3A and B) . A biopsy of the tongue lump also showed squamous tumor cells (Fig. 3D) , similar in appearance to the biopsy of lung. Based on these findings, the tongue lesion was diagnosed as a metastatic tumor from the lung cancer. A positron emission computed tomography (PET-CT)
showed no metastasis to bone, liver, or brain. The patient was diagnosed as T4N0M1b, stage IV left upper lobe lung SCC with metastases to the base of the tongue, according to the TNM staging system. [7] Subsequently, he received platinum-based doublet chemotherapy ( Table 1 ). The DC regimen, which consists of docetaxel (100 mg, d1) and carboplatin (400 mg, d1), repeated every 21 days, was given as first-line treatment on July, 2016. After 2 courses of chemotherapy, the patient underwent CT scan, which revealed a progress of the disease, and he continued to have pain at the base of his tongue. Instead of continuing with the other combination chemotherapy, the patient received a paclitaxel/Nida's platinum regimen (paclitaxel: 210 mg on day 1; Nida's platinum: 400 mg on days 1-4; repeated every 21 days) from September 2016 to the time of he died (February 16, 2017).
Genomic analysis

High-throughput sequencing
Targeted sequencing of the lung cancer tissue was performed at Berry Genomics Co, Ltd (Beijing, China). Targeted sequences were enriched using Integrated DNA Technologies xGen PanCancer Panel v1.5 (Coral, IL). A genomic DNA library was prepared using the Nextera DNA Library Prep Kit (Illumina, San Diego, CA), and was quantified by Eco Real-Time PCR System (Illumina, San Diego, CA). The quantified library was sequenced on the Illumina (San Diego, CA) HiSeq 2500 platform with 2 Â 150 bp configuration.
The average sequencing depth of targeted regions is Â520.9. For bases in targeted regions, 99.92% are covered at least once, and 99.34% have over Â50 read depth.
Data processing
Adaptor sequences and bases with low qualities were trimmed off from the raw reads during preprocessing and quality control by using Flexbar (version 2.4). The reads were then aligned to the hg19 (GRCh37) version of human genome using BurrowsWheeler Aligner, version 0.7.5. The resulted alignments were sorted by SAMtools (version 0.1.19), and after which the PCR duplications were marked using Picard tools (version 1.57). To further increase specific mutation calling, we used Genome Analysis tool kit (version 3.3-0) for realignment and base recalibration. Somatic single nucleotide substitutions were called by combined using of VarScan2 (version 2.3.7) and MuTect (version 1.1.7), and somatic small indels were detected by combined use of SomaticIndelDetector (GATK version 2.3.9) and VarScan2 (version 2.3.7).
Fisher exact test was performed on every locus in which a second allele was detected, to improve the sensitivity of mutation calling. The functional regions and the effects of resulting mutations were annotated by Annovar (ver. 2016Feb01).
Discussion
Primary lung cancer usually presents as an airway mucous membrane irritation, such as cough and blood-stained sputum, whereas primary tongue carcinoma usually presents with tongue lesions, pain, and dysphagia. [8] This patient initially presented with a cough with intermittent bloody sputum and subsequently became aware of a lump on the base of his tongue and experienced pain and hoarseness. According to these clinical characteristics, medical images, and pathological examinations, we diagnosed the tongue lesion as a metastatic tumor from the lung cancer.
Indeed, it is difficult to identify tumors or tuberculosis in a lung cavity lesion. In general, tuberculosis is usually manifested as low fever, night sweats, fatigue, weight loss and other symptoms and blood antituberculosis antibody detection or purified protein derivative (PPD) skin test could be positive. It was too hasty to diagnose this patient as tuberculosis initially without the typical clinical manifestations of tuberculosis and positive laboratory findings.
Reported incidence of metastases from NSCLC to the tongue varies between 0.2% and 1.6%. [6] Primary NSCLC spreads to distant organs by 3 routes: systemic, venous, or lymphatic circulation. [2] Lingual metastases occur mostly in patients whose primary lung cancers are generally disseminated; their prognoses tend to be rather poor (Table 2 ). This patient's rare tongue metastasis likely occurred through lymphatic circulation rather than systemic or venous dissemination, as his PET-CT showed there was no widespread metastasis to other sites. As with primary tumors of the tongue, metastatic lesions to the tongue may be ulcerated or polypoid. [6] Tongue metastasis can also cause pain, bleeding, discomfort, difficulty in swallowing, or dyspnea. Although rare, tongue metastasis should be considered under these circumstances, especially in cases with nonulcerated masses on the base of the tongue; appropriate investigation should be undertaken. [3] Platinum-based doublet chemotherapy has been a standard treatment for patients with advanced stage NSCLC for many years. [9] Improved understanding of the biology of NSCLC has led to a dramatic change in the therapeutic landscape of this disease. Treatment of selected patients with advanced NSCLC that harbors specific oncogenic alterations, including epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, had been revolutionized. [10, 11] Biomarker-driven therapies, such as those for EGFR and ALK, and tyrosine kinase inhibitors (TKIs) such as gefitinib, Table 1 Combination therapeutic regimens and treatment results.
Regiments
Number of courses Treatment results Table 2 Studies of lung cancer with tongue metastasis.
DC
Author, reference
Basic information Pathology Metastatic sites Multimodality therapy
Survival months
Jeba et al [2] 45-yr-old male smoker Adenocarcinoma Tongue, lung, liver, adrenals, kidneys, pancreas, duodenum, intra-abdominal lymph nodes
Carboplatin/pemetrexed chemotherapy Lost to follow-up Terashima et al [3] 63-yr-old male smoker Squamous Tongue, lung, liver, adrenal gland, pericardium, heart, subcutaneous tissues Radiation to lingual lesion, brain, muscular metastases; docetaxel/carboplatin chemotherapy 5 mo
Mui et al [4] 65-yr-old male smoker
Large cell Tongue, bone Radiation to lingual lesion, neck and lung; cisplatin chemotherapy
mo
Kurt et al [6] 57-yr-old male smoker Squamous Tongue, parenchymal nodules, T12 vertebral Cisplatin, docetaxel/cisplatin, gemcitabine chemotherapy
Lost to follow-up Tsubochi et al [16] 39-yr-old male Nonsmoker Adenocarcinoma Lingual tonsillar, jugular, lymphade-nopathy Surgery to lung cancer; radiation to lingual tonsillar 8 yr Xiangwen et al [22] 39-yr-old female Nonsmokers Squamous Tongue, brain, bone Chemotherapy 3 mo erlotinib, afatinibb, and crizotinib have substantially improved the prognosis of selected patients and currently represent the standard first-line treatment of molecularly-defined advanced NSCLC, especially adenocarcinomas. [9, 12] However, these therapies offer no obvious benefits for patients with squamous cell carcinoma. [13] Thankfully, immunotherapy strategies, especially immune checkpoint inhibitors, are a major focus of NSCLC research and therapy. [14] Immune checkpoint inhibitors, including monoclonal antibodies directed against cytotoxic T-lymphocyte-associated antigen-4 (such as ipilimumab and tremelimumab) and programmed cell death protein-1/programmed cell death ligand-1 pathway (such as nivolumab and pembrolizumab), have been shown to induce significant and prolonged clinical responses, with a manageable toxicity profile in patients with advanced NSCLC, for both SCC or adenocarcinoma, independently of any somatically activated oncogenes. [13] We believe that as more and more new drugs are developed and applied to clinical practice, the prognosis of patients with lung cancer will get better and better.
Treatment for primary SCC of the tongue, radiotherapy is as effective as surgery in controlling the tumor and is as associated with a lower rate of complications. Treatment for tongue metastasis arising from malignancies is not standardized. [15] When a tongue mass is relatively small, surgical treatment seems effective. However, for larger tumors, surgery at this site sometimes leads to gross morbidity, with such problems as difficulty with swallowing and speech. [16] In the current case, extirpation of the tumor and lymph nodes by dissection or radiation to the tongue lesion may cause severe complications, because the tumor had spread widely from the root of the tongue, and multiple lymph nodes were also involved.
The patient was initially treated with a first-line regimen of doublet chemotherapy with carboplatin and pemetrexed. However, the disease progressed after 2 cycles of chemotherapy, with worsening performance status. We sequenced 127 cancerrelated genes from this patient's pathologic specimen, and identified 7 mutant genes, including KRAS, PIK3CA, TP53, cyclin-dependent kinase inhibitor 2A (CDKN2A), T-box 3 (TBX3), CCCTC-binding factor (CTCF), and nuclear receptor corepressor 1 (NCOR1) (Fig. 4A-G ), but without EGFR or ALK mutations. This showed no significant differences from patients with metastasis to common sites. [17] KRAS and PIK3CA are in pathways downstream of EGFR, and their mutations induce resistance to EGFR-TKI agents. [18] Current research suggests that KRAS mutation is the main driver of poor prognosis in patients with NSCLC, and also may be a common cause of cancer recurrence, but unfortunately, no drugs are available that directly address KRAS mutation. [19, 20] Mutations leading to the inactivation of Tp53 had also been shown to be frequent in human lung SCCs, and may lead to expansion of mutant stem cell clones. [21] This would lead to disease progression. We expect that pharmacists can develop targeted drugs for new targets, such as KRAS mutation or inactivation of Tp53 in the near future, so that the treatment of lung cancer can have more choices.
We predicted this patient will not be sensitive to targeted therapy, and will have a poor prognosis. Therefore, we chose to continue systemic chemotherapy for him with paclitaxel and Nida's platinum. He had ongoing soreness at the base of his tongue and died about 7 months after the diagnosis of lung cancer.
